Brian Macgillivray
Family Medicine · San Antonio, TXNPI 1851374623
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $77 of the $110 with a category attached, or 70.6%. 5 manufacturers reported payments, led by AbbVie at 38.5% of the total. Reporting peaked in 2019 at $42 and has fallen 88.7% since, to $5 in 2025. That places this record below the midpoint for family medicine clinicians in TX, where the typical reported total is $436.
Across 7 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$42
- Novo Nordisk$32
- Sanofi$16
- Astellas Pharma Global Development$15
- Pfizer$5
Across 1,633 payments — averaging $1992.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$663K
- AbbVie$631K
- Sanofi US Services Inc.$476K
- Novartis$404K
- Pfizer$257K
- Astellas Pharma Global Development$216K
- plus $607K from 18 others
What the payments were for
- Food & beverage$7771%
- Education$3229%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $42 |
| Novo Nordisk | 1 | $32 |
| Sanofi | 1 | $16 |
| Astellas Pharma Global Development | 1 | $15 |
| Pfizer | 1 | $5 |
How this compares
$110 in reported general payments places this provider in the 20th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 15 | $15,904 |
| EliquisApixaban | 14 | $15,011 |
| XareltoRivaroxaban | 14 | $13,523 |
| OzempicSemaglutide | 13 | $12,385 |
| JardianceEmpagliflozin | 12 | $7,212 |
| JanuviaSitagliptin Phosphate | 11 | $5,950 |
| ProgesteroneProgesterone, Micronized | 54 | $2,652 |
| SynthroidLevothyroxine Sodium | 28 | $1,579 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 35 | $1,379 |
| Rosuvastatin Calcium | 92 | $856 |
| Montelukast Sodium | 56 | $779 |
| Tamsulosin Hcl | 39 | $706 |
| Sertraline Hcl | 30 | $648 |
| Alprazolam | 66 | $504 |
| Ezetimibe | 35 | $486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $5 | $15,01114 claims |
| Novo NordiskOzempic | $32 | $12,38513 claims |
| AbbVieSynthroid | $42 | $1,57928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 8,760 family medicine providers in Texas.
Other family medicine in San Antonio
- Aaron KingSan Antonio$1.1M
- Solomon PaleySan Antonio$136K
- Sarah SamreenSan Antonio$133K
- Melissa WalkerSan Antonio$53K
- Paul SaenzSan Antonio$50K
- Carlos CamposNew Braunfels$1.5M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.